Effects of Exercise Training on Cognitive Function and Neurotrophic Factors in Overweight Adults

Obesity Clinical Trial

— BrainFit  

Official title:

Effects of High Intensity Interval- vs Resistance or Combined- Training for Improving Cognitive Function and Neurotrophic Factors in Overweight Adults (BrainFit Study): Factorial Randomised Controlled Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02915913
• Other study ID #: 2016-09-22
• Status: Completed
• Phase: N/A
• Start date: September 2016
• Est. completion date: December 2016

Study information

• Verified date: October 2018
• Source: Universidad Santo Tomas
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The BrainFit Study aims to examine acute effects of High Intensity Interval- vs Resistance or Combined program has benefits on Cognitive Function as well as on secretion and regulation of neurotrophic factors or neurotrophins in a cohort of sedentary, overweight adults (aged 18-30 years) from Bogota, Colombia.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: December 2016
• Est. primary completion date: December 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 30 Years

Eligibility

Inclusion Criteria:

• Written informed consent.

• Interested in improving health and fitness.

• Central obesity: waist circumference =90cm

• Body mass index = 26 kg/m(2)

Exclusion Criteria:

• Systemic infections.

• Weight loss or gain of >10% of body weight in the past 6 months for any reason.

• Currently taking medication that suppresses or stimulates appetite.

• Uncontrolled hypertension: systolic blood pressure 160 mm Hg or diastolic blood pressure 95 mm Hg on treatment.

• Gastrointestinal disease, including self-reported chronic hepatitis or cirrhosis, any episode of alcoholic hepatitis or alcoholic pancreatitis within past year, inflammatory bowel disease requiring treatment in the past year, recent or significant abdominal surgery (e.g., gastrectomy).

• Asthma.

• Diagnosed diabetes (type 1 or 2), fasting impaired glucose tolerance (blood glucose 118 mg/dL), or use of any anti-diabetic medications.

• Currently taking antidepressant, steroid, or thyroid medication, unless dosage is stable (no change for 6 months).

• Any active use of illegal or illicit drugs.

• Current exerciser (>30 min organized exercise per week).

• Indication of unsuitability of current health for exercise protocol (PARQ).

Related Conditions & MeSH terms

• Cognitive Function
• Motor Activity
• Obesity
• Overweight

Intervention

Behavioral:
• Experimental: High Intensity Interval
Walking on a treadmill 4min at 80-90% peak heart rate and recovery 4 min at 65% peak heart rate until expenditure of 500 kcal
• Resistance training
Completing a resistance circuit (including upper and lower muscle groups) as many times as needed according to subject weight until expenditure of 500 kcal
• Plus: High Intensity Interval + Resistance Training
Walking on a treadmill as intervention 1 until 50% the energy expenditure prescribed is reached, then completing a resistance circuit until 100% energy expenditure is reached

Other:
• Non-exercise
This group will receive the usual clinical care according to the consensus recommendations of the national goals for cardiovascular health promotion and disease reduction of the American Heart Association and Colombian guidelines COLDEPORTES.

Locations

Country	Name	City	State
Colombia	Robinson Ramírez-Vélez	Bogota	Cundinamarca

Sponsors (3)

Lead Sponsor	Collaborator
Universidad Santo Tomas	Universidad del Rosario, Universidad Nacional de Colombia

Country where clinical trial is conducted

Colombia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from Baseline in Brain-derived neurotrophic factor	Measurement of serum Brain-derived neurotropic factor true blood samples.	Baseline and 60 minutes immediately after the interventions ends
Secondary	Change from Baseline in Neurotrophin-3		Baseline and 60 minutes immediately after the interventions ends
Secondary	Change from Baseline in Neurotrophin-4		Baseline and 60 minutes immediately after the interventions ends
Secondary	Change from Baseline change in Cognitive Function	Cognitive Performance Test (BPT) computerized cognitive assessment battery developed by Lumos Labs, Inc.	Baseline and 60 minutes immediately after the interventions ends